Mumbai, Milan, December 18, 2025: Global pharma major Lupin Limited (Lupin) today announced that its subsidiaries in the Philippines (Multicare Pharmaceuticals) and Brazil (MedQuimica) have signed an exclusive licensing agreement with Neopharmed Gentili S.p.A, an Italian pharmaceutical company, for marketing and promotional rights for the Gastroenterology brand, Plasil^® (metoclopramide), in their respective markets.

This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets. Neopharmed will oversee product supply in the Philippines, ensuring quality and compliance with global standards. In Brazil, production will be shifted to Medquimica’s manufacturing facility.

“Our partnership with Neopharmed represents a significant milestone in Lupin’s commitment to expand access to Plasil, one of the most potent anti-emetic treatments, across key emerging markets. Our extensive local presence, regulatory expertise, and strong commercial capabilities in the Philippines and Brazil, together with Neopharmed’s distribution network and reach, will broaden patient access and deliver meaningful health outcomes,” said Fabrice Egros, President of Corporate Development, Lupin.

“We are pleased to partner with Lupin to bring Plasil® to two strategic and rapidly growing markets, such as Brazil and the Philippines. This agreement reflects our commitment to expanding Neopharmed’s international footprint, while leveraging Lupin’s strong local presence to ensure that Plasil® is available to every patient in need,” said Matteo Meazzini, Director of Business Development, Neopharmed Gentili.

Plasil^® is widely acknowledged for its efficacy in treating nausea, vomiting, and motility disorders that affect millions of patients.

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn  https://www.linkedin.com/company/lupin

About Neopharmed
Neopharmed Gentili is a pharmaceutical company founded in Italy with historic roots in its territory, which is rapidly expanding beyond national borders thanks to a consolidated and reliable experience in M&A and Licensing transactions, especially with multinational partners. Research, responsibility and care are the pillars that guide Neopharmed Gentili’s mission to improve the health and quality of life of patients, caregivers and healthcare personnel. Neopharmed Gentili’s ambition is to help people live long and healthy lives, acting with ethical value and scientific precision, and offering solutions with high therapeutic value. www.neogen.it

For further information or queries please contact:
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com

*Safe Harbor Statement
Plasil^® is a registered trademark of Neopharmed